Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytrx Cp (CYTR) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 49,980
  • Shares Outstanding, K 96,940
  • Annual Sales, $ 100 K
  • Annual Income, $ -58,590 K
  • 36-Month Beta 1.34
  • Price/Sales 249.90
  • Price/Book 1.89
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.95
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 0.25 on 03/07/08
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.36 +25.00%
on 12/28/16
0.51 -11.76%
on 01/17/17
-0.01 (-2.17%)
since 12/16/16
3-Month
0.36 +25.00%
on 12/28/16
0.74 -39.19%
on 11/29/16
-0.03 (-6.25%)
since 10/17/16
52-Week
0.36 +25.00%
on 12/28/16
3.66 -87.70%
on 04/25/16
-1.37 (-75.27%)
since 01/15/16

Most Recent Stories

More News
CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that,...

Is the Options Market Predicting a Spike in CytRx Corp (CYTR) Stock?

Options traders are pricing in a big move for CytRx Corp (CYTR) shares as it has huge implied volatility

CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer

CytRx Corporation (NASDAQ:CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, has appointed Daniel Levitt,...

CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into securities purchase agreements with existing institutional...

Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the appointment of Earl Warren Brien, M.D., a noted sarcoma surgeon, industry...

CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR) today announced positive updated results from its pivotal Phase 3 clinical trial evaluating aldoxorubicin compared to investigator's choice in patients with relapsed or...

CytRx Reports Third Quarter 2016 Financial Results

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2016, and provided...

Research Reports Coverage on Biotech Stocks -- Tesaro, Aralez Pharma, Rexahn Pharma, and CytRx

In today's pre-market research, Stock-Callers.com takes notice of the Biotech industry, which has had a weak performance this year. The iShares NASDAQ Biotechnology Index is lower over 25% year-to-date,...

CytRx Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial at ESMO 2016 Congress

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today presented results from its on-going Phase 1b/2 trial of aldoxorubicin in combination...

DEADLINE TOMORROW ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against CytRx Corporation and Reminds Investors with Losses In Excess of $100,000 to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 22, 2016 / Khang & Khang LLP (the "Firm") announces a class action lawsuit was filed against CytRx Corporation ("CytRx" or the "Company") (Nasdaq: CYTR). Investors who...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.

See More

Support & Resistance

2nd Resistance Point 0.54
1st Resistance Point 0.49
Last Price 0.45
1st Support Level 0.42
2nd Support Level 0.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.